Miguel Proença, João Marcelino, João Vieira, Joana Guimarães, Carlota Dias, Elza Tomaz
{"title":"Predictors of treatment control in severe chronic urticaria treated with omalizumab.","authors":"Miguel Proença, João Marcelino, João Vieira, Joana Guimarães, Carlota Dias, Elza Tomaz","doi":"10.5415/apallergy.0000000000000162","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Real-life clinical research on biomarkers that predict therapy outcomes of severe chronic spontaneous urticaria patients receiving omalizumab (OMA) therapy is still limited. For this reason, we aimed to identify biomarkers that predict the response to OMA treatment.</p><p><strong>Methods: </strong>A single-center, observational, retrospective review of patients with severe chronic urticaria treated with OMA from January 2015 to January 2023 in a Portuguese Immunology and Allergy Department. One-way ANOVA and linear regression were used.</p><p><strong>Results: </strong>Data on 56 OMA-treated chronic spontaneous urticaria patients shows patients can be divided into 3 groups according to their response to OMA. The first group of 26 patients (46.4%) successfully reduced their IMA dose without experiencing any rebound effects. The second group of 19 (33.9%) patients achieved disease control but could not tolerate a progressive dose reduction, and the third group of 11 (19.6%) patients, required a higher dose to achieve disease control. In group 1, patient age and a favorable clinical response had a positive correlation (<i>P</i> = 0.008). The patient's age was also correlated to the time interval until a dose reduction was tolerated (<i>r</i> = 0.69; <i>P</i> = 0.005). There was also a negative correlation between the ratio: thyroid peroxidase antibodies/total-IgE and a favorable clinical response (<i>r</i> = -0.74; <i>P</i> = 0.021). In group 2, thyroid peroxidase antibodies were negatively correlated with a favorable clinical response (<i>r</i> = -0.55; <i>P</i> = 0.027). In group 3, anti-double-stranded DNA was negatively correlated with a favorable clinical response (<i>r</i> = -0,97; <i>P</i> = 0,007).</p><p><strong>Conclusion: </strong>Our study suggests that older patients experience higher success rates with OMA compared to younger individuals, but increasing age is also associated with a longer interval before achieving successful dose reduction. Potential markers of resistance to OMA identified in our cohort included elevated levels of IgG-antithyroid peroxidase antibodies, positive anti-dsDNA antibodies, and a higher IgG-antithyroid peroxidase/total-IgE ratio.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"15 3","pages":"159-165"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419318/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia Pacific Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5415/apallergy.0000000000000162","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Real-life clinical research on biomarkers that predict therapy outcomes of severe chronic spontaneous urticaria patients receiving omalizumab (OMA) therapy is still limited. For this reason, we aimed to identify biomarkers that predict the response to OMA treatment.
Methods: A single-center, observational, retrospective review of patients with severe chronic urticaria treated with OMA from January 2015 to January 2023 in a Portuguese Immunology and Allergy Department. One-way ANOVA and linear regression were used.
Results: Data on 56 OMA-treated chronic spontaneous urticaria patients shows patients can be divided into 3 groups according to their response to OMA. The first group of 26 patients (46.4%) successfully reduced their IMA dose without experiencing any rebound effects. The second group of 19 (33.9%) patients achieved disease control but could not tolerate a progressive dose reduction, and the third group of 11 (19.6%) patients, required a higher dose to achieve disease control. In group 1, patient age and a favorable clinical response had a positive correlation (P = 0.008). The patient's age was also correlated to the time interval until a dose reduction was tolerated (r = 0.69; P = 0.005). There was also a negative correlation between the ratio: thyroid peroxidase antibodies/total-IgE and a favorable clinical response (r = -0.74; P = 0.021). In group 2, thyroid peroxidase antibodies were negatively correlated with a favorable clinical response (r = -0.55; P = 0.027). In group 3, anti-double-stranded DNA was negatively correlated with a favorable clinical response (r = -0,97; P = 0,007).
Conclusion: Our study suggests that older patients experience higher success rates with OMA compared to younger individuals, but increasing age is also associated with a longer interval before achieving successful dose reduction. Potential markers of resistance to OMA identified in our cohort included elevated levels of IgG-antithyroid peroxidase antibodies, positive anti-dsDNA antibodies, and a higher IgG-antithyroid peroxidase/total-IgE ratio.
期刊介绍:
Asia Pacific Allergy (AP Allergy) is the official journal of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI). Although the primary aim of the journal is to promote communication between Asia Pacific scientists who are interested in allergy, asthma, and clinical immunology including immunodeficiency, the journal is intended to be available worldwide. To enable scientists and clinicians from emerging societies appreciate the scope and intent of the journal, early issues will contain more educational review material. For better communication and understanding, it will include rational concepts related to the diagnosis and management of asthma and other immunological conditions. Over time, the journal will increase the number of original research papers to become the foremost citation journal for allergy and clinical immunology information of the Asia Pacific in the future.